De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Opsens Beheer

Beheer criteriumcontroles 3/4

De CEO Opsens' is Louis Laflamme, benoemd in Jan2013, heeft een ambtstermijn van 10.92 jaar. De totale jaarlijkse vergoeding van { bedraagt CA$ 425.37K, bestaande uit 76.9% salaris en 23.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.59% van de aandelen van het bedrijf, ter waarde CA$ 1.98M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 9.9 jaar.

Belangrijke informatie

Louis Laflamme

Algemeen directeur

CA$425.4k

Totale compensatie

Percentage CEO-salaris	76.9%
Dienstverband CEO	10.9yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	9.9yrs

Recente managementupdates

Recent updates

Opsens Inc. (TSE:OPS) Just Reported And Analysts Have Been Lifting Their Price Targets

Nov 23

Analyse CEO-vergoeding

Hoe is Louis Laflamme's beloning veranderd ten opzichte van Opsens's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Aug 31 2023	n/a	n/a	-CA$12m
May 31 2023	n/a	n/a	-CA$15m
Feb 28 2023	n/a	n/a	-CA$13m
Nov 30 2022	n/a	n/a	-CA$13m
Aug 31 2022	CA$425k	CA$327k	-CA$11m
May 31 2022	n/a	n/a	-CA$9m
Feb 28 2022	n/a	n/a	-CA$6m
Nov 30 2021	n/a	n/a	-CA$4m
Aug 31 2021	CA$397k	CA$279k	-CA$1m
May 31 2021	n/a	n/a	CA$622k
Feb 28 2021	n/a	n/a	CA$1m
Nov 30 2020	n/a	n/a	-CA$179k
Aug 31 2020	CA$342k	CA$274k	-CA$3m
May 31 2020	n/a	n/a	-CA$5m
Feb 29 2020	n/a	n/a	-CA$6m
Nov 30 2019	n/a	n/a	-CA$5m
Aug 31 2019	CA$566k	CA$254k	-CA$2m
May 31 2019	n/a	n/a	-CA$2m
Feb 28 2019	n/a	n/a	-CA$2m
Nov 30 2018	n/a	n/a	-CA$3m
Aug 31 2018	CA$308k	CA$249k	-CA$5m
May 31 2018	n/a	n/a	-CA$4m
Feb 28 2018	n/a	n/a	-CA$5m
Nov 30 2017	n/a	n/a	-CA$5m
Aug 31 2017	CA$225k	CA$190k	-CA$7m

Compensatie versus markt: De totale vergoeding ($USD 312.94K ) Louis } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 754.25K ).

Compensatie versus inkomsten: De vergoeding van Louis is gestegen terwijl het bedrijf verliesgevend is.

CEO

Louis Laflamme

10.9yrs

Tenure

CA$425,365

Compensatie

Mr. Louis Laflamme, C.A, C.P.A., serves as Director at Icentia Inc. He had been an Interim Chief Financial Officer of Opsens Inc. since December 09, 2022 until March 27, 2023. He has been the Chief Executi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Alan Milinazzo	Executive Chairman of the Board	4.8yrs	CA$99.20k	0.063% CA$ 210.3k
Louis Laflamme	CEO, President & Director	10.9yrs	CA$425.37k	0.59% CA$ 2.0m
Brad Davis	Chief Commercial Officer	1.8yrs	CA$756.25k	geen gegevens
John Hannigan	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Pierre Poulin	Corporate Controller	no data	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van OPS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Alan Milinazzo	Executive Chairman of the Board	4.8yrs	CA$99.20k	0.063% CA$ 210.3k
Louis Laflamme	CEO, President & Director	10.9yrs	CA$425.37k	0.59% CA$ 2.0m
Jean Lavigueur	Independent Director	11.9yrs	CA$152.64k	0.27% CA$ 899.0k
Denis Sirois	Independent Director	17.2yrs	CA$152.94k	0.38% CA$ 1.3m
Gaetan Duplain	Director	17.2yrs	CA$294.71k	3.31% CA$ 11.1m
James Mackin	Independent Director	7.3yrs	CA$210.38k	0.038% CA$ 126.6k
Denis Harrington	Independent Director	8.9yrs	CA$90.45k	0.017% CA$ 58.0k
Lori Chmura	Independent Director	2.3yrs	CA$136.74k	geen gegevens

9.9yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van OPS wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.9 jaar).

Opsens Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Independent Director recently sold CA$79k worth of stock

Insufficient new directors

Opsens Inc., Annual General Meeting, Jan 24, 2023

Opsens Inc. Announces Departure of Robin Villeneuve as Corporate Secretary, Effective December 9, 2022

CFO & Corporate Secretary exercised options to buy CA$115k worth of stock.

CFO & Corporate Secretary exercised options and sold CA$75k worth of stock

Recent updates

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.

New minor risk - Share price stability

Forecast to breakeven in 2025

Opsens Inc. to Report Q3, 2023 Results on Jul 13, 2023

Potential Upside For Opsens Inc. (TSE:OPS) Not Without Risk

New major risk - Financial position

OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR Study

Independent Director recently sold CA$79k worth of stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Consensus forecasts updated

No longer forecast to breakeven

First quarter 2023 earnings: Revenues exceed analyst expectations

Opsens Inc. to Report Q1, 2023 Results on Jan 12, 2023

Opsens Inc. has completed a Follow-on Equity Offering in the amount of CAD 10 million.

Price target decreased to CA$3.73

Consensus EPS estimates fall by 27%

Consensus EPS estimates fall by 21%

Full year 2022 earnings: EPS misses analyst expectations

Opsens Inc. to Report Q4, 2022 Results on Nov 22, 2022

Opsens Inc. to Report Q4, 2022 Results on Nov 22, 2022

Insufficient new directors

Opsens Inc., Annual General Meeting, Jan 24, 2023

Opsens Inc. Announces Departure of Robin Villeneuve as Corporate Secretary, Effective December 9, 2022

Opsens Inc. Announces First Savvywire Clinical Cases in Europe and Launch of Safe-Tavi Study

Opsens Announces First Savvywire Procedure in the United States by Dr. Philippe Genereux of Morristown Medical Center

OpSens Inc. Announces FDA Clearance for the SavvyWire for Use in Transcatheter Aortic Valve Replacement (TAVR) Procedures

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast breakeven date pushed back to 2024

Opsens Inc. to Report Q3, 2022 Results on Jul 14, 2022

CFO & Corporate Secretary exercised options to buy CA$115k worth of stock.

CFO & Corporate Secretary exercised options and sold CA$75k worth of stock

Opsens Inc. Announces New Data Supporting the Safety and Efficacy of its SavvyWire Recently Approved by Health Canada for Transcatheter Aortic Valve Replacement Procedures

Insufficient new directors

Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire

Consensus EPS estimates fall by 69%

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Opsens Inc. to Report Q2, 2022 Results on Apr 13, 2022

Insufficient new directors

Insufficient new directors

OpSens Inc Appoints Brad Davis as Chief Commercial Officer

Independent Director exercised options to buy CA$245k worth of stock.

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Opsens Inc. Announces 510(K) Submission to U.S. FDA for New Guidewire for the Tavr Procedure

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CA$4.28

Opsens Inc. Successfully Completes 20-Patient in Human Clinical Study for TAVR Procedure

Independent Director recently sold CA$139k worth of stock

Independent Director exercised options to buy CA$368k worth of stock.

President exercised options and sold CA$230k worth of stock

Director recently bought CA$310k worth of stock

Director recently bought CA$310k worth of stock

Price target increased to CA$3.79

OPSENS Receives Approval from Health Canada to Initiate First In-Man Clinical Study for its New Guidewire for the TAVR Procedure

Insufficient new directors

Independent Director recently bought CA$150k worth of stock

Independent Director recently bought CA$150k worth of stock

Consensus forecasts updated

Third quarter 2021 earnings released

Opsens (TSE:OPS) Has Debt But No Earnings; Should You Worry?

Price target increased to CA$3.00

Second quarter 2021 earnings released: EPS CA$0.001 (vs CA$0.015 loss in 2Q 2020)

Price target raised to CA$2.56

Opsens Inc. has completed a Follow-on Equity Offering in the amount of CAD 25 million.